

MATERIALS LICENSE Amendment No. 09

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. St. Anthony Medical Center	In accordance with application received October 23, 1984
2. Main and Franciscan Road Crown Point, IN 46307	3. License number 13-15933-01 is amended in its entirety to read as follows:
	4. Expiration date July 31, 1990
	5. Docket or Reference No. 030-10047
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35
	8. Maximum amount that licensee may possess at any one time under this license
	A. As necessary for uses authorized in Subitem 9.A
	B. 2 curies of each byproduct material authorized in Subitem 6.B
	C. As necessary for uses authorized in Subitem 9.C
	D. As necessary for uses authorized in Subitem 9.D
	E. 1 curie total for all sources authorized in Subitem 6.E

8507150212 850621
REG3 LIC30
13-15933-01 PDR

COPY 2
m130

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

13-15933-01

Docket or Reference number

030-10047

Amendment No. 09

F. Xenon-133

F. Gas or gas in solution
that is the subject
of an active (i.e., not
withdrawn or terminated)
"New Drug Application"
(NDA) approved by FDA or
an active (i.e., not
withdrawn, terminated
or on "clinical hold")
"Notice of Claimed
Investigational Exemption
for a New Drug" (IND)
that has been accepted
by FDA

F. 100 millicuries

G. Any byproduct material
listed in Section
31.11(a) of 10 CFR 31

G. Prepackaged kits

G. 3millicuries
of each byproduct
material authorized
in Subitem 6.G

H. Americium 241

H. Sealed source Amersham/
Searle Model No. AMC.24

H. 2 sources not to
exceed 15
millicuries each

9. Authorized Use

- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- F. Blood flow studies. Pulmonary function studies.

COPY

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
13-15933-01

Docket or Reference number
030-10047

Amendment No. 09

G. In vitro studies

- H. To be used in a Siemens Gammasonics Model 035-42300C source assembly as a motion correction point source in conjunction with a gamma camera imaging system.

CONDITIONS

10. Licensed material shall be used only at licensee's facilities located at Main and Franciscan Road, Crown Point, Indiana.
11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Leon Kinasiewicz, M.D. Groups I, II, III, IV and V
Xenon-133
In vitro studies

J. K. Dixit, M.D. Groups I, II and III
Xenon-133
In vitro studies

H. S. Kim, M.D. Groups I, II and III
Xenon-133
In vitro studies

Abdul J. Kahn, M.D. Group VI

Mir J. Shah, M.D. Group VI

13. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:
- (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
 - (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
 - (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
13-15933-01

Docket or Reference number
030-10047

Amendment No. 09

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem (a) above and of the license(s) specified in Subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under Subitem (a) above.

- 14.. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
15. A. (1) Each sealed source containing licensed material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed six months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, a sealed source received from another person shall not be put into use until tested.
- (2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.
- (3) The periodic leak test required by this condition does not apply to sealed sources that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to any use or transfer to another person unless they have been leak tested within six months prior to the date of use or transfer.
- B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.
- C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within five (5) days of the test with the U. S. Nuclear Regulatory Commission, Region III, 799 Roosevelt Road, Glen Ellyn, Illinois 60137, describing the equipment involved, the test results, and the corrective action taken.
- D. Tests for leakage and/or contamination shall be performed by or by other persons specifically authorized by the Commission or an Agreement State to perform such services.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
13-15993-01

Docket or Reference number
030-10047

Amendment No. 09

16. Patients containing Cobalt 60, Cesium 137 or Iridium 192 implants shall remain hospitalized until a source count and surveys made with an appropriate radiation detection instrument indicate that all implants have been removed. The results of these surveys shall be recorded and maintained for inspection by the Commission for five (5) years from the time the implants are removed.
17. Patients containing Iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.
18. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:
 - A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
 - B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
 - C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.
19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application received October 23, 1984; letter received November 13, 1984, letter dated June 10, 1985; model ALARA program as contained in Appendix O of Regulatory Guide 10.8, October, 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed

By James Mullauer

Materials Licensing Section, Region III

Date June 21, 1985

COPY